Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study by Heo, Jung-Yoon et al.
Agoraphobia and Follicle-Stimulating
Hormone Levels between Tamoxifen
and Goserelin versus Tamoxifen
Alone in Premenopausal Hormone
Receptor-Positive Breast Cancer: A 12-
Month Prospective Randomized Study
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Heo, Jung-Yoon, Hawoo Yi, Maurizio Fava, David Mischoulon,
Kiwon Kim, Sechang Yoon, Hong Jin Jeon, and Jeong Eon Lee.
2017. “Agoraphobia and Follicle-Stimulating Hormone Levels
between Tamoxifen and Goserelin versus Tamoxifen Alone in
Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-
Month Prospective Randomized Study.” Psychiatry Investigation 14




Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Print ISSN 1738-3684 / On-line ISSN 1976-3026
OPEN ACCESS
  Copyright © 2017 Korean Neuropsychiatric Association  491
ORIGINAL ARTICLE
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ObjectiveaaTamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression 
and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety and depression symptoms and FSH lev-
els who received conventional tamoxifen alone and combination treatment of goserelin, a gonadotropin-releasing hormone (GnRH) an-
alogue, with tamoxifen.
MethodsaaSixty-four premenopausal women with hormone receptor-positive early-stage breast cancer were included and were as-
signed randomly to receive either tamoxifen and goserelin combination or tamoxifen alone for 12 months. The participants were evaluat-
ed blindly using the Hamilton Depression and Anxiety Rating Scale, the Beck Depression Rating Scale, and the Albany Panic and Pho-
bia Questionnaire (APPQ). Blood FSH levels were assessed at baseline, 6 and 12 months.
ResultsaaA significant time×group difference was detected in the agoraphobia trends subscale of the APPQ and in FSH levels. The 
combination group showed significantly less increases in agoraphobia subscale of APPQ and greater decreases in FSH level than those 
in the tamoxifen-alone group from baseline to 12 months of treatment. No significant differences for age, tumor grade, body mass index, 
or family history were found at baseline between the two groups. 
ConclusionaaOur results suggest that the combination treatment of tamoxifen and goserelin resulted in less agoraphobia than tamoxi-
fen alone in premenopausal women with breast cancer, which may associated with FSH suppression of goserelin.
 Psychiatry Investig 2017;14(4):491-498
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INTRODUCTION
Breast cancer is a sex hormone-dependent disease. Ap-
proximately 60% of breast cancers in premenopausal women 
are hormone receptor positive (HR+). Adjuvant endocrine 
therapy reduces tumor recurrence and mortality in premeno-
pausal women with estrogen receptor-positive, progesterone 
receptor-positive, or both.1 Recently, diverse types of approach 
for endocrine therapy has developed and been tested under 
trials.
Tamoxifen is a selective modulator of estrogen and has been 
the standard care for premenopausal women with HR+ breast 
cancer for many ayears.2-4 The anti-cancer effect originates from 
binding estrogen receptors on tumors. This binding produces 
a nuclear complex that decreases DNA synthesis and inhibits 
the effects of estrogen. Tamoxifen increases plasma estradiol 
concentrations by interfering with the normal negative pitu-
itary feedback mechanisms,5,6 and the resulting follicle-stimu-
lating hormone (FSH) rise drives ovarian steroidogenesis and 
increased incidence of ovarian cysts.7
Goserelin is a gonadotropin-releasing hormone (GnRH) an-
alogue acts on the pituitary gland in the brain.8 Administration 
of goserelin with chemotherapy appeared to protect against 
ovarian failure, reducing the risk of early menopause and im-
proving prospects for fertility.9 Initially, goserelin causes an 
increase in the amount of FSH and LH released from the pi-
tuitary gland, but chronic administration act by downregulat-
ing pituitary GnRH receptors, thereby suppressing the release 
of luteinising hormone (LH) and FSH.10 Goserelin reduces 
plasma/serum FSH and circulating sex hormone levels in 
premenopausal women to postmenopausal levels.11,12 
The treatment effect of tamoxifen plus goserelin for breast 
cancer has been controversial. However, the recent study re-
sults of the Suppression of Ovarian Function Trial (SOFT) and 
the Tamoxifen and Exemestane Trial (TEXT) showed that 
ovarian function suppression with goserelin improved the sur-
vivals in premenopausal breast cancer patients after adjuvant 
chemotherapy.13,14 
One of the major side effects of adjuvant chemotherapy in 
young patients with breast cancer is treatment-associated pre-
mature menopause.15 Many previous studies have reported 
that changes of hormone levels are closely related to depres-
sion and anxiety disorders.16-18 Compared to normal meno-
pause, treatment-associated menopause is more abrupt in 
onset and more persistent. Treatment-associated menopause 
has been linked to poor health perception, leading to increased 
emotional stress and anxiety, particularly in young patients 
with breast cancer.19 Even in a general population of women 
without lifetime history of psychiatric diseases, women who 
enter the menopausal transition earlier have a significant risk 
for first onset of depression.20 However the adverse effects of 
goserelin have not been studied well in young patients with 
breast cancer.
The aim of this study was to compare anxiety and depression 
symptoms of premenopausal women with HR+ early-stage 
breast cancer who received either a combination of tamoxifen 
plus goserelin or tamoxifen therapy alone, using psychologi-
cal measures, and follicle-stimulating hormone (FSH) levels, 
in a 12-month prospective randomized trial. 
METHODS
Subjects
A total of 64 patients with breast cancer were recruited 
from the outpatient clinic of the Breast and Endocrine Sur-
gery Center of Samsung Medical Center between January 
2011 and December 2014. Patients were eligible to participate 
in the study after meeting the following inclusion criteria: 
age <50 years and premenopausal women with histological-
ly-proven, HR+ (defined as ER ≥10% and/or PgR ≥10%) ear-
ly invasive breast cancer. 
The patient exclusion criteria were: age >50 years, natural 
menopause, GnRH level ≥40 pg/mL, pregnancy or lactation, 
and uncontrolled heart failure or coronary heart disease in 
the previous 6 months. Those with a psychotic disorder (e.g., 
schizophrenia or delusional disorder), bipolar affective disor-
der, or neurological illness, including significant cognitive 
impairment or Parkinson’s disease, mental retardation, a sig-
nificant medical condition, epilepsy, history of alcohol or drug 
dependence, personality disorder, or brain damage were ex-
cluded. 
Study procedures 
 Eligible patients were randomized using a 1:1 allocation to 
one of the two treatment groups from the date of randomiza-
tion. One group of patients received a combined treatment of 
tamoxifen and goserelin (n=32), and the second group received 
tamoxifen alone (n=32) for 12 months. All patients attended 
three visits at baseline and at 6 and 12 months after treatment 
was initiated. Patients who were unable to tolerate the study 
medications per protocol were withdrawn from the study. 
This study protocol was approved by the ethics review board 
of Samsung Medical Center, Seoul, Korea. Signed informed 
consent was obtained from all participants. 
Baseline psychological evaluation 
 Psychiatrists with more than 3 years of clinical experience 
evaluated the participants’ psychiatric and medical histories 
and confirmed their eligibility. A trained psychologists blind-
ed to the psychiatrists’ assessment evaluated the participants’ 
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psychiatric diagnoses and current mood states using the Ko-
rean version of the Mini-International Neuropsychiatric In-
terview (MINI).21 The psychiatric evaluations were adminis-
tered by a single trained rater at baseline and at 6 and 12 months.
Psychological measurements
The primary outcome measures were the Hamilton De-
pression Rating Scale (HAM-D)22 and the Hamilton Anxiety 
Rating Scale (HAM-A)23 scores of the participants. The sec-
ondary outcome measures were changes in the Beck Depres-
sion Inventory (BDI) score.24 The Albany Panic and Phobia 
Questionnaire (APPQ),25 and the Anxiety Sensitivity Index-
Revised (ASI-R)26 scores were obtained and FSH levels were 
measured at each visit. In addition, Mood Disorder Question-
naire (MDQ)27 and the Hypomania Checklist (HCL-32) were 
employed to measure the severity of previous hypomanic ep-
isodes.28 
The current anxiety sensitivity level of the participants was 
assessed using the ASI-R. The Korean version of the ASI-R has 
demonstrated a high internal consistency coefficient (α=0.92) 
and a good test-retest reliability (r=0.82).29 The APPQ is a 
27-item self-report questionnaire designed to measure fear 
of agoraphobic situations (Agoraphobia, 9 items), fear of so-
cial situations (Social phobia, 10 items), and fear of activities 
that produce somatic sensations (interoceptive fear, 8 items). 
The Korean version of the APPQ has excellent psychometric 
properties, which are similar to the original APPQ.30 The BDI 
is a well-performing, 21-item, self-report questionnaire de-
signed to assess and evaluate the frequency of depressive symp-
toms over a 1-week period. We administered the Korean ver-




Blood (10 mL) was taken from the cubital vein of each par-
ticipant into 1) heparinized vacuum containers (plasma), 2) 
additive-free vacuum containers (serum), and 3) EDTA vacu-
um containers (for platelet count). FSH was measured using a 
chemiluminescence immunoassay and an ADVIA Centaur au-
tomated analyzer (Siemens Healthcare Diagnostics, New York, 
NY, USA). The assay detection limit was 0.3 IU/L. 
Statistical analysis
The chi-square or Fisher’s exact test were used to compare 
sociodemographic and clinical categorical data between the 
two groups, and the t-test was used for normally distributed 
continuous variables. The primary efficacy measures were 
changes in the HAM-D and HAM-A scores and from base-
line to 12 months. The Linear Mixed Model was applied to 
repeated measurements (after natural log transformation due 
to non-normality in some cases). Blood FSH levels had skewed 
distributions and were transformed using the natural log. The 
Generalized Linear Mixed model was applied to repeated or-
dinal outcomes. Time, group and time×group were consid-
ered fixed effects and subject was considered a random effect. 
We performed simple and multiple linear regression analy-
sis for univariable analysis and multivariable analysis, respec-
tively. Variables with a p-value of less than 0.2 in the univariable 
analysis were included in the multivariable analysis.
Two-tailed p-values<0.05 were considered significant and 
were corrected using Bonferroni’s method for multiple test-
ing. All statistical analyses were performed using SAS ver. 9.4 
software (SAS Institute, Cary, NC, USA). 
 
RESULTS
The demographic and clinical profiles of the patients are 
shown in Table 1. No differences in the demographic or clin-
ical variables were detected at baseline between the two treat-
ment groups. The mean age of the combined treatment group 
was 44.75±3.26 years and that in the tamoxifen-alone group 
was 44.97±3.26 years. 
Table 2 presents the baseline psychological characteristics. 
Mean baseline HAM-D scores were 5.72±3.53 vs. 6.06±3.91 
in the combined treatment and tamoxifen-alone groups, re-
spectively. No differences were observed in HAM-D, HAM-
A, MDQ, HCL-32, ASI and APPQ scores at baseline (Table 2). 
No differences in baseline FSH levels were detected between 
the treatment groups (Table 1 and 2).
Table 3 shows the psychological characteristics of the pa-
tients in the two groups. A significant time×group difference 
was detected in the agoraphobia trends subscale of the APPQ 
and in FSH levels (Figure 1) between the two groups after 12 
months of treatment. The tamoxifen and goserelin group 
showed significantly less of an increase in APPQ agoraphobia 
subscale score but a greater decrease in FSH level than those 
in the tamoxifen-alone group from baseline to 12 months of 
treatment. No significant time, group, or time×group differenc-
es were observed in the HAM-D and BDI score between the 
two groups (Table 3 and Figure 1).
A time-dependent ascending trend was detected in the to-
tal HAM-A score (β coefficient=1.90, p=0.01) (Table 3 and Fig-
ure 1), the HAM-D genital symptom subscale score (β coeffi-
cient=4.07, p<0.001), and the HAM-A intellectual (p<0.001), 
somatosensory (p<0.001), and autonomic symptom (p=0.01) 
subscales. The total HAM-D scores of all patients after 12 
months of treatment were ≤7 points (no depression).32 A to-
tal of 41.9% of the combined treatment group and 44.8% of 
the tamoxifen-alone group showed moderate to severe anxiety.
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DISCUSSION 
This is the first study to compare anxiety and depressive 
symptoms and FSH levels between premenopausal women 
with breast cancer who received either a combined tamoxifen 
and goserelin treatment or a tamoxifen-alone treatment. The 
tamoxifen and goserelin group showed significantly less of an 
increase in agoraphobia symptoms but a greater decrease in 
FSH level than those in the tamoxifen-alone group from base-
line to 12 months of treatment, whereas no differences were 
observed in depressive symptoms between the groups. 
It is a unique finding of this study that agoraphobia symp-
Table 1. Baseline demographic and clinical characteristics of the study subjects
Characteristics
Tamoxifen+Goserelin group (N=32) Tamoxifen group (N=32) Statistics
Mean SD Mean SD t p
Age (years) 44.75 3.26 44.97 3.26 -0.27 0.38
35–39 yr, No. (%) 01 (3.13) 03 (9.38)
40–49 yr, No. (%) 31 (96.87) 29 (90.62)
BMI 22.48 2.00 23.05 1.95 -1.44 0.26
Tumor size (cm) 01.22 0.39 00.89 0.51 2.91 0.01
FSH (mIU/mL) 09.45 8.90 08.81 7.56 0.32 0.75
No. % No. % χ2 p
FHx (+) 07 21.9 05 15.6 0.41 0.52
FHx (-) 25 78.1 27 84.4 1.02 0.31
Nuclear grade 
Low 12 37.5 16 50.0 1.02 0.31
Intermediate 20 62.5 16 50.0
Histological grade 
Well 22 68.8 26 81.3 1.33 0.25
Noderated 10 31.3 06 18.8
C-erbb-2 IHC
Negative  13 40.6 12 37.5 2.07 0.36
+ 19 59.4 18 56.3
++ 00 00 02 06.3
Ki-67
≤14% 19 59.4 25 78.1 2.62 0.11
>14% 13 40.6 07 21.9
BMI: body mass index, FSH: follicle-stimulating hormone, FHx: family history, C-erbb-2 IHC: C-erbb-2 (Her-2/neu) Immunohistochemis-
try, Ki-67: Ki-67 protein 
Table 2. Baseline psychological characteristics of the participants
Characteristics
Tamoxifen+Goserelin group (N = 32) Tamoxifen group (N=32) Statistics
Mean SD Mean SD t p
HAM-D 5.72 3.35 6.06 3.91 -0.38 0.71
HAM-A 7.44 4.15 7.44 4.39 -0 1
MDQ 3.41 3.06 3.91 3.88 -0.57 0.57
HCL32 5.84 5.47 6.41 5.747 -0.40 0.69
ASI 17.46 26.18 18.48 20.44 -1.60 0.11
APPQ 35.29 31.66 46.14 32.14 -1.22 0.23
BDI 8.03 6.12 7.97 5.37 -0.43 0.97
HAM-D: Hamilton Depression Rating Scale, HAM-A: Hamilton Anxiety Rating Scale, MDQ: Mood Disorder Questionnaire, HCL32: Hypo-
mania Symptom Checklist 32, ASI: Anxiety Sensitivity Index, APPQ: Albany Panic and Phobia Questionnaire, STAI: State-Trait Anxiety In-
ventory
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toms are found in premenopausal women with breast cancer 
during anti-cancer treatment with tamoxifen. Agoraphobia 
is a type of anxiety symptoms which characterized by anxiety 
in situations where the sufferer perceives the environment to 
be dangerous, uncomfortable, or unsafe, which can include 
wide-open spaces, uncontrollable social situations, unfamil-
iar places, shopping malls, airports, and bridges. Although ag-
oraphobia became independent of panic disorder in the Fifth 
Edition of the Diagnostic and Statistical Manual (DSM-5), ag-
oraphobia commonly occurs in patients with panic disorder.33 
Although previous preclinical studies revealed that tamoxi-
fen treatment may provoke anxiety symptoms due to antago-
nize the effects of ovarian hormones in preclinical studies,34,35 
human studies showed that changes in anxiety, mood, and 
sexual functioning were not significantly associated with 
treatment of tamoxifen in placebo-controlled, double-blind, 
randomized, controlled trials that investigated the efficacy of 
tamoxifen in the prevention of breast cancer in women who 
are at high familial risk.36
This study showed that tamoxifen and goserelin group 
showed significantly less of an increase in agoraphobia symp-
toms than tamoxifen-alone group. Goserelin is a GnRH ana-
logue that increases FSH and luteinizing hormone (LH) syn-
thesis, leading to increase levels of circulating sex steroids.37 
In this study, FSH levels were suppressed remarkably in the 
combined treatment group relative to those in the tamoxifen-
alone group. Mean FSH level in the tamoxifen-alone group 
peaked within the first 6 months, and then tended to stabilize 
at a high level. In contrast, mean FSH level in the combined 
treatment group decreased and remained stable. 
Previous studies have revealed that anxiety is commonly 
found in women in perimenopause,38 in those with premen-
strual dysphoric disorder,39 and in the postpartum,40 indicat-
ing fluctuations in hypothalamic-pituitary-gonadal axis ac-
Table 3. Psychological characteristics of the patients with breast cancer assigned randomly to 12 months of treatment with tamoxifen and 
goserelin or tamoxifen alone 
Variables
Tamoxifen+Goserelin Tamoxifen-alone Analysis (p)
Baseline 6 mon 12 mon Baseline 6 mon 12 mon Time Group Time group
HAM-D totala 5.72 (3.35) 6.50 (3.22) 5.71 (3.58)0 6.06 (3.91) 5.87 (4.19) 5.72 (3.76) <0.71 <0.93 <0.48
Genital subscale, N (%)b <0.001** <0.29 <0.44
Score 0 23 (71.88) 14 (43.75) 14 (43.75) 22 (68.75) 18 (58.06) 11 (37.93)
Score 1 or 2 9 (28.13) 18 (56.25) 18 (56.25) 10 (31.25) 13 (41.94) 18 (62.07) 
HAM-A totala 7.44 (4.15) 0 9.06 (4.26) 8.94 (5.83)0 7.44 (4.39)0 8.42 (4.83) 9.31 (5.45) <0.01* <0.95 <0.52
Intellectual subscale, N (%)b <0.001** <0.67 <0.79
Score 0 16 (50.00) 11 (34.38) 10 (32.26) 15 (46.88) 9 (29.03) 6 (20.69)
Score 1 13 (40.63) 17 (53.13) 13 (41.94) 16 (50.00) 19 (61.29) 15 (51.72) 
Score 2 or 3 3 (9.38) 0 4 (12.5)0 8 (25.80) 1 (3.13)0 3 (9.68)0 8 (27.59) 
Somatic (sensory) subscale, N (%)b <0.001** <0.21 <0.67
Score 0 13 (40.63) 6 (18.75) 7 (22.58) 17 (53.13) 10 (32.26) 6 (20.69) 
Score 1 15 (46.88) 17 (53.13) 13 (41.94) 14 (43.75) 16 (51.61) 14 (48.28)  
Score 2 or 3 4 (12.5)0 9 (28.13) 11 (34.49) 1 (3.13)0 5 (16.13) 9 (31.03) 
Autonomic subscale, N (%)b <0.01* <0.31 <0.91
Score 0 17 (53.13) 10 (31.25) 11 (35.48) 20 (62.5)0 14 (45.16) 10 (34.48) 
Score 1 12 (37.5) 0 15 46.88) 12 (38.71) 9 (28.13) 12 (38.71) 15 (51.72) 
Score 2 3 (9.38) 0 7 (21.88) 8 (25.81) 3 (9.38) 0 5 (16.13) 4 (13.79) 
APPQ agoraphobiaa 12.25 (10.99) 13.29 (12.34) 11.74 (9.85)0 16.46 (12.08) 13.26 (8.10)0 18.35 (10.67) <0.29 <0.16 <0.03*
BDIa 8.03 (6.1)00 9.25 (7.37) 7.33 (6.59)0 7.97 (5.37)0 8.42 (5.78)0 7.83 (5.25) <0.46 <0.97 <0.47
FSH (mIU/mL)a 9.47 (8.89)0 1.92 (1.02) 2.05 (1.47)0 8.82 (7.56)0 13.41 (9.06)0 13.13 (8.81) <0.001** <0.001** <0.001**
aLinear Mixed Model was applied to repeated measurements. In some cases, natural logarithm transformation was done due to non-normality. 
Time, group and time×group were considered fixed effects and subject was considered a random effect, bGeneralized Estimated Equation 
Model was applied to repeated ordinal outcomes. *p<0.05, **p<0.01. HAM-D: Hamilton Depression Rating Scale, HAM-A: Hamilton Anxiety 
Rating Scale, ASI: Anxiety Sensitivity Index, APPQ: Albany Panic and Phobia Questionnaire, BDI: Beck Depression Inventory, Genital sub-
scale: loss of libido, impaired sexual performance, menstrual disturbances; Intellectual subscale: difficulty concentrating, poor memory; Somat-
ic (sensory) subscale: tinnitus, blurring of vision, hot and cold flushes, feeling of weakness, pricking sensation; Autonomic subscale: dry mouth, 
flushing, pallor, tendency to sweat, giddiness, tension 
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tivities that may result in anxiety symptoms. A previous 
study showed that perimenopausal fluctuation of FSH level 
may interact with the psychosocial environment of midlife 
stress to contribute to perimenopausal anxiety and depres-
sion risk through alterations in regulation of the HPA axis by 
γ-aminobutyric acid (GABA).41 This suggests that suppress 
FSH fluctuation from combination treatment of goserelin 
and tamoxifen can reduce anxiety symptoms among breast 
cancer patients, because breast cancer patients experience 
high stress due to cancer diagnosis, regular checks for recur-
rence, and body changes from breast surgery.42
Another possible effects of a decrease in estrogen levels on 
the serotonin system43,44 have been associated with psychiat-
ric symptoms. Women with breast cancer are at higher risk 
for experiencing hot flushes, which are largely attributable to 
systemic cancer treatment and their effects on estrogen levels.45 
Menopausal symptoms and complications, such as hot flush-
es, sweating, and heart palpitations, are related to anxiety in 
breast cancer survivors.46 Hot flush severity is also associated 
with higher FSH and lower estrogen levels, early menopause, 
beginning the late menopausal stage at a younger age, and 
greater anxiety.47 
Our results should be considered in light of several limita-
tions. Although the sample size was moderate, a larger sam-
ple size could offer more certain conclusions. We did not mea-
sure gonadal sex steroid hormone levels, such as estrogen and 
progesterone; thus, we could not evaluate the direct causal 
relationship between anxiety and these hormone levels. The 
relationship between hormonal changes and mood before 
and after adjuvant endocrine therapy is complex and appears 
to be influenced by study design and multiple psychiatric 
and environmental factors. A future study should have a lon-
ger treatment period with more frequent follow-up visits to 
accurately assess changes in hormone levels and mood symp-
toms. More accurate clinical assessments and use of validated 
measures would allow menopause-related somatic complaints 
and psychological symptoms to be distinguished at greater 
levels for diagnostic and therapeutic purposes. 
In conclusion, our results suggest that the combined tamox-
ifen and goserelin treatment for premenopausal women with 
breast cancer resulted in less frequent agoraphobia symp-
toms than those observed with tamoxifen alone. Both treat-
ment regimens increased somatic anxiety levels. Therefore, 
agoraphobia and anxiety symptoms should be carefully ob-
served in patients treated for breast cancer with anti-estrogen 
therapy.
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